HDLBP and Associated Diseases
According to the implementation of gene therapy-associated technologies, excellent scientists in Creative Biolabs are good at transforming basic science and personalized medicine research through classical and contemporary approaches. We are glad to provide detailed and one-stop services for our clients all over the world.
Overview of HDLBP
High density lipoprotein binding protein (HDLBP, also known as Vigilin) is a 141 kDa gene encoding product containing 1268 amino acids. HDLBP can bind high density lipoprotein. HDLBP plays an important role in cell sterol metabolisms like plasma lipoprotein assembly, remodeling, and clearance, and regulates the excess cholesterol levels to protect the cells from the damage caused by the over-accumulation of cholesterol. HDLBP can also bind to RNA and induce the formation of heterochromatin.
HDLBP in Disease
HDLBP is associated with different diseases and cancers such as chromosome 2q37 deletion syndrome and hepatocellular carcinoma.
- Chromosome 2q37 deletion syndrome
Haploinsufficiency of HDLBP caused by deletion of chromosome 2q37 is associated with chromosome 2q37 deletion syndrome. The 2q37 deletion syndrome is characterized by a 3.5 Mb deletion on the region of 2q37.3. The 2q37 deletion syndrome is a 2q37 breakpoint-induced disorder with typical phenotypes such as occasional major malformations and developmental delay. The deleted genes containing HDLBP in 2q37.3 are verified by FISH analysis and microsatellite genotyping. According to the RNA expression analysis, HDLBP is downregulated in patients with the 2q37 deletion syndrome compared with their family members or healthy individuals.
- Hepatocellular carcinoma
HDLBP is related to the proliferation and drug resistance of hepatocellular carcinoma (HCC). Compared with noncancerous liver tissues, the expression of HDLBP is enriched in the region in HCC. Sorafenib therapy is used to reduce the tumor burden in advanced HCC patients. The knockdown of HDLBP by short-interfering RNAs will inhibit the proliferation and sorafenib resistance of the HCC cell line, which will be enhanced by the overexpression of HDLBP. RAF1 is the downstream gene of HDLBP demonstrated by mass spectrometry screening and is stabilized by HDLBP in promoting the progression of HCC. Thus, HDLBP can be the new therapeutic target for HCC.
Fig.1 HDLBP expression is associated with the progression of HCC. (Yuan, 2022)
Creative Biolabs, as a world-renowned trusted biotechnology company, has a skilled team of well-trained scientists with years of experience in the field of gene therapy. For all your questions about gene therapy, please feel free to contact us for more details about your HDLBP project.
References
- Felder, B.; et al. FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome. Am. J. Med. Genet. 2009, 149A: 952–959.
- Yuan, J.; et al. HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation. Cellular and Molecular Gastroenterology and Hepatology. 2022: S2352345X22002168.
